Filtering by:
Bladder CancerFDA Approves Jelmyto (Mitomycin gel) for Urothelial Cancer
The US Food and Drug Administration (FDA) approved Jelmyto (mitomycin gel) for a type of urothelial cancer, which is a cancer of the lining of the urinary system.
FDA Approves Padcev (Enfortumab vedotin-ejfv) for Bladder Cancer
The US Food and Drug Administration (FDA) has approved a new type of drug for certain people with bladder cancer.
FDA Approves First Targeted Therapy for Bladder Cancer
The US Food and Drug Administration (FDA) has approved Balversa (erdafitinib) as the first targeted therapy for bladder cancer.
Study: Outcomes Similar for Robotic vs. Traditional Bladder Cancer Surgery
Surgeons at 15 medical centers in the US have compared the outcomes of robotic surgery to traditional open surgery for bladder cancer. The study found outcomes to be similar for both types of surgery.
Bladder and Breast Cancer Survivor Finds Road To Recovery
The third time Judy Halter heard the words, “You have cancer,” she panicked. “I knew there was a possibility that my time here could definitely be shortened,” she said. But even more than her diagnosis of bladder cancer, Halter says she worried about how she was going to get to treatment.
FDA Approves Keytruda (Pembrolizumab) for Any Tumor with Specific Genetic Change
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug Keytruda (pembrolizumab) to include tumors with a specific genetic change regardless of cancer type.
FDA Approves Bavencio (Avelumab) for Bladder Cancer
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Bavencio (avelumab) to treat people with advanced urothelial carcinoma, the most common type of bladder cancer.
FDA Approves Imfinzi (Durvalumab) for Bladder Cancer
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Imfinzi (durvalumab) to treat people with advanced urothelial carcinoma, the most common type of bladder cancer.
